Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients
Eli Lilly and Company (NYSE: LLY) has announced the launch of new 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials for $499 per month through the new Zepbound Self Pay Journey Program. The company has also reduced prices of existing 2.5 mg vials to $349 and 5 mg vials to $499 per month.
These offerings are available exclusively through LillyDirect Self Pay Pharmacy Solutions, which provides transparent pricing by eliminating third-party supply chain entities and allowing patients to access savings directly outside of insurance.
The Zepbound Self Pay Journey Program reduces the regular prices of 7.5 mg ($599) and 10 mg ($699) doses to $499 per month at first fill and refills occurring within 45 days of prior delivery.
Zepbound is also available in various dosages in single-dose pen autoinjectors, with recommended maintenance dosages of 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly.
Eli Lilly and Company (NYSE: LLY) ha annunciato il lancio di nuove fiale monodose da 7,5 mg e 10 mg di Zepbound (tirzepatide) al prezzo di $499 al mese attraverso il nuovo Programma Zepbound Self Pay Journey. L'azienda ha anche ridotto i prezzi delle fiale esistenti da 2,5 mg a $349 e da 5 mg a $499 al mese.
Queste offerte sono disponibili esclusivamente tramite LillyDirect Self Pay Pharmacy Solutions, che fornisce prezzi trasparenti eliminando le entità della catena di fornitura di terze parti e consentendo ai pazienti di accedere ai risparmi direttamente al di fuori dell'assicurazione.
Il Programma Zepbound Self Pay Journey riduce i prezzi regolari delle dosi da 7,5 mg ($599) e 10 mg ($699) a $499 al mese al primo acquisto e per i rifornimenti che avvengono entro 45 giorni dalla consegna precedente.
Zepbound è disponibile anche in diverse dosi in autoiniettori a penna monodose, con dosaggi di mantenimento raccomandati di 5 mg, 10 mg o 15 mg iniettati sottocute una volta alla settimana.
Eli Lilly and Company (NYSE: LLY) ha anunciado el lanzamiento de nuevos frascos de dosis única de 7.5 mg y 10 mg de Zepbound (tirzepatida) por $499 al mes a través del nuevo Programa Zepbound Self Pay Journey. La compañía también ha reducido los precios de los frascos existentes de 2.5 mg a $349 y de 5 mg a $499 al mes.
Estas ofertas están disponibles exclusivamente a través de LillyDirect Self Pay Pharmacy Solutions, que proporciona precios transparentes al eliminar entidades de la cadena de suministro de terceros y permitir a los pacientes acceder a ahorros directamente fuera del seguro.
El Programa Zepbound Self Pay Journey reduce los precios regulares de las dosis de 7.5 mg ($599) y 10 mg ($699) a $499 al mes en la primera compra y los recargas que ocurren dentro de los 45 días de la entrega anterior.
Zepbound también está disponible en varias dosis en autoinyectores de pluma de dosis única, con dosis de mantenimiento recomendadas de 5 mg, 10 mg o 15 mg inyectadas subcutáneamente una vez a la semana.
엘리 릴리 앤 컴퍼니 (NYSE: LLY)는 새로운 7.5mg 및 10mg Zepbound (tirzepatide) 단일 용량 바이알을 월 $499에 출시한다고 발표했습니다. 또한 기존 2.5mg 바이알의 가격을 $349로, 5mg 바이알의 가격을 $499로 인하했습니다.
이 제품들은 LillyDirect Self Pay Pharmacy Solutions를 통해서만 이용할 수 있으며, 제3자 공급망을 제거하여 투명한 가격을 제공하고 환자들이 보험 외부에서 직접 절약할 수 있도록 합니다.
Zepbound Self Pay Journey 프로그램은 7.5mg ($599) 및 10mg ($699) 용량의 정가를 첫 번째 구매 시 및 이전 배송 후 45일 이내의 리필 시 $499로 인하합니다.
Zepbound는 또한 단일 용량 펜 자가 주사기에서 다양한 용량으로 제공되며, 주 1회 피하 주사를 권장하는 유지 용량은 5mg, 10mg 또는 15mg입니다.
Eli Lilly and Company (NYSE: LLY) a annoncé le lancement de nouveaux flacons à dose unique de 7,5 mg et 10 mg de Zepbound (tirzepatide) au prix de 499 $ par mois via le nouveau programme Zepbound Self Pay Journey. L'entreprise a également réduit les prix des flacons existants de 2,5 mg à 349 $ et de 5 mg à 499 $ par mois.
Ces offres sont disponibles exclusivement via LillyDirect Self Pay Pharmacy Solutions, qui offre des prix transparents en éliminant les entités de la chaîne d'approvisionnement tierces et en permettant aux patients d'accéder directement aux économies en dehors de l'assurance.
Le programme Zepbound Self Pay Journey réduit les prix réguliers des doses de 7,5 mg ($599) et 10 mg ($699) à 499 $ par mois lors de la première commande et des renouvellements effectués dans les 45 jours suivant la livraison précédente.
Zepbound est également disponible en différentes dosages dans des auto-injecteurs à stylo à dose unique, avec des dosages d'entretien recommandés de 5 mg, 10 mg ou 15 mg injectés sous-cutanément une fois par semaine.
Eli Lilly and Company (NYSE: LLY) hat die Einführung neuer 7,5 mg und 10 mg Zepbound (Tirzepatid) Einzeldosen-Vials für 499 $ pro Monat im Rahmen des neuen Zepbound Self Pay Journey Programms angekündigt. Das Unternehmen hat auch die Preise für bestehende 2,5 mg Vials auf 349 $ und 5 mg Vials auf 499 $ pro Monat gesenkt.
Diese Angebote sind ausschließlich über LillyDirect Self Pay Pharmacy Solutions erhältlich, die transparente Preise bietet, indem sie Dritte in der Lieferkette ausschließt und es den Patienten ermöglicht, direkt außerhalb der Versicherung Einsparungen zu erzielen.
Das Zepbound Self Pay Journey Programm senkt die regulären Preise für 7,5 mg ($599) und 10 mg ($699) Dosen auf 499 $ pro Monat bei der ersten Bestellung und Nachfüllungen, die innerhalb von 45 Tagen nach der vorherigen Lieferung erfolgen.
Zepbound ist auch in verschiedenen Dosierungen in Einmal-Pen-Autoinjektoren erhältlich, mit empfohlenen Erhaltungsdosierungen von 5 mg, 10 mg oder 15 mg, die einmal wöchentlich subkutan injiziert werden.
- Launch of new 7.5 mg and 10 mg Zepbound vials at $499/month
- Price reduction of 2.5 mg vials to $349/month and 5 mg vials to $499/month
- Introduction of Zepbound Self Pay Journey Program offering discounts on higher doses
- Direct-to-consumer distribution model eliminating third-party costs
- insurance coverage for obesity treatments remains a barrier to broader adoption
- Self-pay model indicates continued challenges with insurance reimbursement
Insights
Eli Lilly's expansion of Zepbound's self-pay options represents a strategic market disruption in the obesity treatment landscape, with significant implications for patients, competitors, and payers alike.
The introduction of 7.5 mg and 10 mg single-dose vials at
By bypassing third-party supply chain entities through LillyDirect, Lilly is executing a vertical integration strategy that accomplishes multiple objectives:
- Capturing margin typically lost to intermediaries
- Creating price transparency in an opaque market
- Building direct relationships with patients
- Collecting valuable real-world usage data
While
The timing is particularly noteworthy as Lilly competes fiercely with Novo Nordisk's Wegovy in the GLP-1 weight loss market. This pricing strategy could accelerate Zepbound's market penetration, especially as manufacturing constraints have availability of these medications. With obesity affecting over 40% of American adults, even capturing a small percentage of self-pay patients represents substantial revenue potential.
Investors should recognize this as part of Lilly's broader strategy to establish dominance in the cardiometabolic space. By creating more affordable access points now, Lilly is building brand loyalty and patient familiarity that could translate to significant market advantage if broader insurance coverage materializes in the future—positioning the company for both immediate self-pay revenue and potential long-term reimbursed market expansion.
New 7.5 mg and 10 mg Zepbound single-dose vials now available for
2.5 mg and 5 mg vial prices reduced
"The OAC applauds Lilly for another step forward in improving the affordability of obesity treatment," said Joe Nadglowski, president and CEO of the Obesity Action Coalition. "However, we still have a long way to go in building a health care system that provides comprehensive care, coverage and payment of such care for people with obesity that is free of weight bias."
Self-pay patients with obesity now have additional Zepbound vial options, including 2.5 mg, 5 mg, 7.5 mg and 10 mg doses. In addition to expanding the doses available, Lilly is taking steps to make Zepbound vials more affordable, including:
- Lowering the price of the 2.5 mg dose to
$349 - Lowering the price of the 5 mg dose to
$499 - Launching the Zepbound Self Pay Journey Program, which reduces the price of the 7.5 mg (
$599 $699 $499
"Every major medical organization and establishment recognizes obesity as a chronic disease, yet insurance and federal programs do not systematically cover people living with obesity for medical care — this needs to change," said Patrik Jonsson, executive vice president and president of Lilly Cardiometabolic Health and Lilly
Zepbound is also available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL doses in a single-dose pen (autoinjector). The recommended maintenance dosages are 5 mg, 10 mg or 15 mg injected subcutaneously once weekly. Those starting on Zepbound will take Zepbound 2.5 mg for four weeks before increasing their dosage to 5 mg.
To learn more about the Zepbound single-dose vial, please visit Zepbound.lilly.com. To learn more about LillyDirect, please visit LillyDirect.lilly.com.
About Zepbound (tirzepatide) injection
Zepbound is the first and only dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity medication. Zepbound tackles an underlying cause of excess weight. It reduces appetite and how much you eat. Zepbound is indicated for adults with obesity, or some adults who are overweight and also have at least one weight-related medical problem, to lose weight and keep it off. Additionally, Zepbound is FDA-approved to treat adults with moderate-to-severe obstructive sleep apnea and obesity. Zepbound should be used with a reduced-calorie diet and increased physical activity. It should not be used in children under 18 years of age or with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. Zepbound has not been studied in patients with a history of pancreatitis, or with severe gastrointestinal disease, including severe gastroparesis, and it is unknown if patients with a history of pancreatitis are at higher risk for developing pancreatitis on Zepbound.
About LillyDirect
LillyDirect is a digital health platform offering disease management resources that make it easier for people living with chronic conditions to access quality care and personalized information, with the goal of improving lifestyle choices across diet, exercise, sleep, and stress management. LillyDirect also offers direct home delivery of select Lilly medicines through third-party pharmacy dispensing services, ensuring patients receive their safe, effective, and FDA-approved Lilly medicines from a secure and trusted source. Prescription fulfillment through LillyDirect is open to all
INDICATIONS AND SAFETY SUMMARY WITH WARNINGS
Zepbound® (ZEHP-bownd) is an injectable prescription medicine that may help adults with:
- obesity, or some adults with overweight who also have weight-related medical problems to lose excess body weight and keep the weight off.
- moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA.
It should be used with a reduced-calorie diet and increased physical activity.
Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.
Warnings - Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.
- Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).
- Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound.
Zepbound may cause serious side effects, including:
Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away.
Kidney problems (kidney failure). Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration.
Gallbladder problems. Gallbladder problems have happened in some people who use Zepbound. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.
Inflammation of the pancreas (pancreatitis). Stop using Zepbound and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back.
Serious allergic reactions. Stop using Zepbound and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.
Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Zepbound with medicines that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery.
Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Zepbound.
Depression or thoughts of suicide. You should pay attention to changes in your mood, behaviors, feelings or thoughts. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you.
Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Zepbound may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Zepbound before you are scheduled to have surgery or other procedures.
Common side effects
The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn. These are not all the possible side effects of Zepbound. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.
Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.
Before using Zepbound
- Your healthcare provider should show you how to use Zepbound before you use it for the first time.
- Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea which could increase your risk of low blood sugar. Talk to your healthcare provider about low blood sugar levels and how to manage them.
- If you take birth control pills by mouth, talk to your healthcare provider before you use Zepbound. Birth control pills may not work as well while using Zepbound. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Zepbound and for 4 weeks after each increase in your dose of Zepbound.
Review these questions with your healthcare provider:
❑ Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❑ Do you take diabetes medicines, such as insulin or sulfonylureas?
❑ Do you have a history of diabetic retinopathy?
❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❑ Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?
❑ Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Zepbound may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Zepbound. It is not known if Zepbound passes into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Zepbound.
- Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Zepbound during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Lilly at 1-800-LillyRx (1-800-545-5979).
How to take
- Read the Instructions for Use that come with Zepbound.
- Use Zepbound exactly as your healthcare provider says.
- Use Zepbound with a reduced-calorie diet and increased physical activity.
- Zepbound is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.
- Use Zepbound 1 time each week, at any time of the day.
- Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection.
- If you take too much Zepbound, call your healthcare provider, seek medical advice promptly, or contact a Poison Center expert right away at 1-800-222-1222.
Zepbound injection is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL in single-dose pen or single-dose vial.
Learn more
Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979) or go to www.zepbound.lilly.com.
This summary provides basic information about Zepbound but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Zepbound and how to take it. Your healthcare provider is the best person to help you decide if Zepbound is right for you.
ZP CON BS 20DEC2024
Zepbound® and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
LillyDirect® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
* The in-person and telehealth providers listed on the LillyDirect site are independent. Treatment decisions and prescribing practices are made based on the independent medical judgment of the provider's care team. They may prescribe medication or another course of treatment.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY
Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995), including statements about the supply and access of Zepbound (tirzepatide) as a treatment for adults with obesity or overweight and reflects Lilly's current belief and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there can be no guarantee that future study results will be consistent with the results to date, that Zepbound will receive additional regulatory approvals, or that Lilly will execute its strategy as planned. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
- Zepbound Self Pay Journey Program lowers the price of the 7.5 mg and 10 mg vials only on first fill and when prescriptions are refilled within 45 days of their previous delivery. 7.5 mg and 10 mg vials are priced at
$599 $699
PP-ZP-US-1660 02/2025 ©Lilly
Refer to: | Niki Biro; niki_biro@lilly.com; 317-358-79074 (Media) |
Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-launches-additional-zepbound-vial-doses-and-offers-new-savings-for-self-pay-patients-302383878.html
SOURCE Eli Lilly and Company
FAQ
What new Zepbound dosages did Lilly (LLY) launch in February 2025?
How much did Lilly reduce the price of Zepbound 2.5 mg and 5 mg vials?
How does the Zepbound Self Pay Journey Program work for LLY's higher doses?
Where can patients access Lilly's new Zepbound vial pricing?
What is the recommended starting dose for Zepbound according to Lilly (LLY)?
